Wisconsin startup Isomark has developed a breath-based test that can detect infection within two hours of its onset. The patented concept has wide-reaching applications – for instance, it’s proposed developing a smart neonatal incubator that’s constantly checking a preemie’s breath for signs of sepsis.
The company has received $2.2 million now in NIH-backed SBIR grants; the device is in the midst of a 110-patient trial at the University of Wisconsin. Read more about its technology here.
The general idea, however, is that by using the non-invasive measurement of breath-based biomarkers, patients could be diagnosed and treated much quicker than if they wait for a lab’s results of, say, a blood test. The uses for Isomark’s test include initial disease detection in a clinic and other outpatient medical services, and importantly, post-op monitoring of patients who could contract hospital-acquired infections like sepsis.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.